Samsung & Exo: $100M Investment in Medical Imaging
- Samsung is reportedly considering an investment in Exo, a California-based startup focused on handheld medical imaging technology.
- Sands Capital, Bold Capital, and Qubit Health Capital are reportedly leading the round.
- Exo, established in 2015, develops handheld devices that combine artificial intelligence, silicon technology, and medical imaging for ultrasound examinations, such as echocardiograms and lung scans.
Samsung may inject $100 million into medical imaging, eyeing a strategic investment in exo, a cutting-edge medical device startup. This bold move, reported by sources, signals Samsung’s intent to claim a significant position in the handheld ultrasound market. Exo, known for its innovative AI-powered devices, develops technology connecting to smartphones, enabling remote medical analysis. This potential injection of capital,led by investors including Sands Capital,will likely accelerate Exo’s commercialization plans. News Directory 3 is following this news closely. Explore how this investment reshapes point-of-care ultrasound technology and the future of diagnostics.Discover what’s next …
Samsung Eyes Potential Investment in Medical Imaging Startup Exo
Samsung is reportedly considering an investment in Exo, a California-based startup focused on handheld medical imaging technology. The potential funding round for the medical device company could reach $100 million, according to Bloomberg, citing unnamed sources.
Sands Capital, Bold Capital, and Qubit Health Capital are reportedly leading the round. Imar Ishrak, chairman of Qubit, is expected to join Exo’s board.
Exo, established in 2015, develops handheld devices that combine artificial intelligence, silicon technology, and medical imaging for ultrasound examinations, such as echocardiograms and lung scans. The devices connect to smartphones,enabling medical professionals to scan patients,document findings,and share reports via a single application.
To date, Exo has secured over $320 million from investors, including RA Capital Management, BlackRock, Intel, Sony, Avidity Partners and Sands Capital. Their most recent funding round, a Series C, raised $220 million in 2021.
Exo is also exploring a potential partnership with Samsung Medison Co., a manufacturer of ultrasound diagnostics and digital X-ray systems.
What’s next
The investment could bolster Exo’s efforts to further develop and commercialize its handheld medical imaging devices, possibly expanding access to point-of-care ultrasound technology.